Eligibility required conventional-imaging mHSPC with ≥1 [68Ga]Ga-PSMA-11–avid lesion; 1:1 randomization to 6 cycles 7.4 GBq q6w plus ADT/ARPI vs ADT/ARPI. Confirmed PSA90 responses numerically improved with radioligand intensification: 83.8% vs 78.1% at week 12, 87.4% vs 81.9% at week 24, and 84.7% vs 80.5% at week 48.
Courtney Flaherty
Geo Focus
Coverage Attributes:
Beta
Informative:
46
%
Data Driven:
43
%
Interviews Q&as:
5
%
Events:
4
%
Themes Covered:
Not enough data
Pitching Insights
Courtney's coverage predominantly focuses on healthcare and pharmaceuticals, specifically cancer research, clinical trials, treatment advancements, biomarkers, and oncology. Her articles heavily cite data and include expert commentary.
To effectively reach out to Courtney Flaherty, consider providing access to relevant data or studies that support the pitch. Additionally, offering a reputable expert who can provide insightful commentary on the latest trends in cancer research or advancements in oncology treatments would be highly beneficial for engagement.
As her geographic focus is not specified but her topics are quite specific to scientific and medical fields, it’s essential to ensure that any outreach provides valuable content related to these areas without being limited by geographical constraints.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Journalist
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
